면역 레퍼토리 시퀀싱 시장 규모, 점유율, 동향 분석 보고서 : 제품 및 서비스별, 유형별, 용도별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)

Immune Repertoire Sequencing Market Summary

The global immune repertoire sequencing market size was estimated at USD 328.2 million in 2024 and is projected to reach USD 894.2 million by 2033, growing at a CAGR of 11.89% from 2025 to 2033. The increasing adoption of next-generation sequencing technologies, applications in immunotherapy and vaccine development, and investments in precision medicine research drive the market growth.

Global Immune Repertoire Sequencing Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global immune repertoire sequencing market report based on product & service, type, application, end-use, and region:

• Product & Service Outlook (Revenue, USD Million, 2021 - 2033)
• Instruments
• Assay Kits & Reagents
  • TCR kits
  • BCR kits
  • Others
• Services
• Type Outlook (Revenue, USD Million, 2021 - 2033)
• Bulk immune repertoire sequencing
• Single cell immune repertoire sequencing
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Oncology & Cancer Immunotherapy
• Autoimmune & Inflammatory Diseases
• Infectious Diseases & Vaccine Development
• Transplantation & Immune Tolerance
• Others
• End-use Outlook (Revenue, USD Million, 2021 - 2033)
• Academic & Research Institutes
• Pharmaceutical & Biotechnology Companies
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• MEA
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
  • 1.2.1. Product & Service Segment
  • 1.2.2. Type Segment
  • 1.2.3. Application Segment
  • 1.2.4. End use Segment
• 1.3. Information analysis
• 1.4. Market formulation & data visualization
• 1.5. Data validation & publishing
• 1.6. Information Procurement
  • 1.6.1. Primary Research
• 1.7. Information or Data Analysis
• 1.8. Market Formulation & Validation
• 1.9. Market Model
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Insights Landscape

Chapter 3. Immune Repertoire Sequencing Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Growing adoption of personalized medicine
    • 3.2.1.2. Rising prevalence of immune-related diseases
    • 3.2.1.3. Advancements in high-throughput sequencing technologies
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost of sequencing technologies
    • 3.2.2.2. Complex data analysis and interpretation
• 3.3. Immune Repertoire Sequencing Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis

Chapter 4. Immune Repertoire Sequencing Market: Product & Service Estimates & Trend Analysis

• 4.1. Product & Service Segment Dashboard
• 4.2. Global Immune Repertoire Sequencing Market Product & Service Movement Analysis
• 4.3. Global Immune Repertoire Sequencing Market Size & Trend Analysis, by Product & Service, 2021 to 2033 (USD Million)
• 4.4. Instruments
  • 4.4.1. Instruments market estimates and forecasts 2021 to 2033 (USD Million)
• 4.5. Assay Kits & Reagents
  • 4.5.1. Assay Kits & Reagents market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.5.2. TCR kits
    • 4.5.2.1. TCR kits market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.5.3. BCR kits
    • 4.5.3.1. BCR kits market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.5.4. Others
    • 4.5.4.1. Others market estimates and forecasts 2021 to 2033 (USD Million)
• 4.6. Services
  • 4.6.1. Services market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Immune Repertoire Sequencing Market: Type Estimates & Trend Analysis

• 5.1. Type Segment Dashboard
• 5.2. Global Immune Repertoire Sequencing Market Type Movement Analysis
• 5.3. Global Immune Repertoire Sequencing Market Size & Trend Analysis, by Type, 2021 to 2033 (USD Million)
• 5.4. Bulk immune-repertoire sequencing
  • 5.4.1. Bulk immune-repertoire sequencing market estimates and forecasts 2021 to 2033 (USD Million)
• 5.5. Single-cell immune-repertoire sequencing
  • 5.5.1. Single-cell immune-repertoire sequencing market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Immune Repertoire Sequencing Market: Application Estimates & Trend Analysis

• 6.1. Application Segment Dashboard
• 6.2. Global Immune Repertoire Sequencing Market Application Movement Analysis
• 6.3. Global Immune Repertoire Sequencing Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
• 6.4. Oncology & Cancer Immunotherapy
  • 6.4.1. Oncology & Cancer Immunotherapy market estimates and forecasts 2021 to 2033 (USD Million)
• 6.5. Autoimmune & Inflammatory Diseases
  • 6.5.1. Autoimmune & Inflammatory Diseases market estimates and forecasts 2021 to 2033 (USD Million)
• 6.6. Infectious Diseases & Vaccine Development
  • 6.6.1. Infectious Diseases & Vaccine Development market estimates and forecasts 2021 to 2033 (USD Million)
• 6.7. Transplantation & Immune Tolerance
  • 6.7.1. Transplantation & Immune Tolerance market estimates and forecasts 2021 to 2033 (USD Million)
• 6.8. Others
  • 6.8.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Immune Repertoire Sequencing Market: End Use Estimates & Trend Analysis

• 7.1. End Use Segment Dashboard
• 7.2. Global Immune Repertoire Sequencing Market End Use Movement Analysis
• 7.3. Global Immune Repertoire Sequencing Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
• 7.4. Academic & Research Institutes
  • 7.4.1. Academic & Research Institutes market estimates and forecasts 2021 to 2033 (USD Million)
• 7.5. Pharmaceutical & Biotechnology Companies
  • 7.5.1. Pharmaceutical & Biotechnology Companies market estimates and forecasts 2021 to 2033 (USD Million)
• 7.6. Others
  • 7.6.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Immune Repertoire Sequencing Market: Regional Estimates & Trend Analysis by Product & Service, Type, Application, and End Use

• 8.1. Regional Market Share Analysis, 2024 & 2033
• 8.2. Regional Market Dashboard
• 8.3. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
• 8.4. North America
  • 8.4.1. North America market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.2. U.S.
    • 8.4.2.1. Key country dynamics
    • 8.4.2.2. Regulatory framework
    • 8.4.2.3. Competitive scenario
    • 8.4.2.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.3. Canada
    • 8.4.3.1. Key country dynamics
    • 8.4.3.2. Regulatory framework
    • 8.4.3.3. Competitive scenario
    • 8.4.3.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.4. Mexico
    • 8.4.4.1. Key country dynamics
    • 8.4.4.2. Regulatory framework
    • 8.4.4.3. Competitive scenario
    • 8.4.4.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
• 8.5. Europe
  • 8.5.1. Europe market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.2. UK
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.3. Germany
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.4. France
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Regulatory framework
    • 8.5.4.3. Competitive scenario
    • 8.5.4.4. France market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.5. Italy
    • 8.5.5.1. Key country dynamics
    • 8.5.5.2. Regulatory framework
    • 8.5.5.3. Competitive scenario
    • 8.5.5.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.6. Spain
    • 8.5.6.1. Key country dynamics
    • 8.5.6.2. Regulatory framework
    • 8.5.6.3. Competitive scenario
    • 8.5.6.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.7. Norway
    • 8.5.7.1. Key country dynamics
    • 8.5.7.2. Regulatory framework
    • 8.5.7.3. Competitive scenario
    • 8.5.7.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.8. Sweden
    • 8.5.8.1. Key country dynamics
    • 8.5.8.2. Regulatory framework
    • 8.5.8.3. Competitive scenario
    • 8.5.8.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.9. Denmark
    • 8.5.9.1. Key country dynamics
    • 8.5.9.2. Regulatory framework
    • 8.5.9.3. Competitive scenario
    • 8.5.9.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
• 8.6. Asia Pacific
  • 8.6.1. Asia Pacific market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.2. Japan
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.3. China
    • 8.6.3.1. Key country dynamics
    • 8.6.3.2. Regulatory framework
    • 8.6.3.3. Competitive scenario
    • 8.6.3.4. China market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.4. India
    • 8.6.4.1. Key country dynamics
    • 8.6.4.2. Regulatory framework
    • 8.6.4.3. Competitive scenario
    • 8.6.4.4. India market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.5. Australia
    • 8.6.5.1. Key country dynamics
    • 8.6.5.2. Regulatory framework
    • 8.6.5.3. Competitive scenario
    • 8.6.5.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.6. South Korea
    • 8.6.6.1. Key country dynamics
    • 8.6.6.2. Regulatory framework
    • 8.6.6.3. Competitive scenario
    • 8.6.6.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.7. Thailand
    • 8.6.7.1. Key country dynamics
    • 8.6.7.2. Regulatory framework
    • 8.6.7.3. Competitive scenario
    • 8.6.7.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
• 8.7. Latin America
  • 8.7.1. Latin America market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7.2. Brazil
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7.3. Argentina
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
• 8.8. MEA
  • 8.8.1. MEA market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.8.2. South Africa
    • 8.8.2.1. Key country dynamics
    • 8.8.2.2. Regulatory framework
    • 8.8.2.3. Competitive scenario
    • 8.8.2.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.8.3. Saudi Arabia
    • 8.8.3.1. Key country dynamics
    • 8.8.3.2. Regulatory framework
    • 8.8.3.3. Competitive scenario
    • 8.8.3.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.8.4. UAE
    • 8.8.4.1. Key country dynamics
    • 8.8.4.2. Regulatory framework
    • 8.8.4.3. Competitive scenario
    • 8.8.4.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.8.5. Kuwait
    • 8.8.5.1. Key country dynamics
    • 8.8.5.2. Regulatory framework
    • 8.8.5.3. Competitive scenario
    • 8.8.5.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company/Competition Categorization
• 9.2. Strategy Mapping
• 9.3. Company Market Position Analysis, 2024
• 9.4. Company Profiles/Listing
  • 9.4.1. QIAGEN
    • 9.4.1.1. Company overview
    • 9.4.1.2. Financial performance
    • 9.4.1.3. Product benchmarking
    • 9.4.1.4. Strategic initiatives
  • 9.4.2. New England Biolabs
    • 9.4.2.1. Company overview
    • 9.4.2.2. Financial performance
    • 9.4.2.3. Product benchmarking
    • 9.4.2.4. Strategic initiatives
  • 9.4.3. Takara Bio
    • 9.4.3.1. Company overview
    • 9.4.3.2. Financial performance
    • 9.4.3.3. Product benchmarking
    • 9.4.3.4. Strategic initiatives
  • 9.4.4. Illumina, Inc.
    • 9.4.4.1. Company overview
    • 9.4.4.2. Financial performance
    • 9.4.4.3. Product benchmarking
    • 9.4.4.4. Strategic initiatives
  • 9.4.5. iRepertoire
    • 9.4.5.1. Company overview
    • 9.4.5.2. Financial performance
    • 9.4.5.3. Product benchmarking
    • 9.4.5.4. Strategic initiatives
  • 9.4.6. BGI
    • 9.4.6.1. Company overview
    • 9.4.6.2. Financial performance
    • 9.4.6.3. Product benchmarking
    • 9.4.6.4. Strategic initiatives
  • 9.4.7. Danaher
    • 9.4.7.1. Company overview
    • 9.4.7.2. Financial performance
    • 9.4.7.3. Product benchmarking
    • 9.4.7.4. Strategic initiatives
  • 9.4.8. Creative Biolabs
    • 9.4.8.1. Company overview
    • 9.4.8.2. Financial performance
    • 9.4.8.3. Product benchmarking
    • 9.4.8.4. Strategic initiatives
  • 9.4.9. Nucleus Biotech
    • 9.4.9.1. Company overview
    • 9.4.9.2. Financial performance
    • 9.4.9.3. Product benchmarking
    • 9.4.9.4. Strategic initiatives
  • 9.4.10. Celemics, Inc.
    • 9.4.10.1. Company overview
    • 9.4.10.2. Financial performance
    • 9.4.10.3. Product benchmarking
    • 9.4.10.4. Strategic initiatives